Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (4928)	2/16/1999 12:01:00 PM
From: Marconi	Respond to of 5736

Inventor mom curbs tears This PR strikes me as YELLOW JOURNALISM. Perhaps this overwrought pitch is how new capital device markets are generated in Africa and China. Not! Best regards, m

To: JanyBlueEyes who wrote (4928)	3/4/1999 10:08:00 AM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 5736

News - Chromatics Comments on Stock Price Change NEW YORK, March 4 /PRNewswire/ -- Chromatics Color Sciences International, Inc. (Nasdaq: CCSI - news) today said that regarding the recent drop in the Company's common stock price, there have been no negative or adverse developments in the Company's operations. Chromatics Chief Executive Officer Darby Macfarlane said, ''To the contrary, we have had a steady stream of good news in recent weeks and continue to move forward with our business plan. The Company's recently announced roll-out is proceeding as planned with initial distribution and in-servicing of its Colormate® TLc-BiliTest(TM) System to hospitals and physicians.'' In February the Company announced that it had completed the first manufacturing run of its non-invasive bilirubin monitoring system for newborns and that it had commenced shipping orders for the Colormate® TLc- BiliTest(TM) System and the TLc-Lensette(TM) calibration standards. Ms. Macfarlane commented today, ''We are very pleased with the response the product has received from physicians and neonatal nurses at the hospitals shipped to date.'' The Colormate® TLc-BiliTest(TM) System (TLc for tender, loving care) is the first device with FDA clearance for commercial use for pain-free, non- invasive monitoring of bilirubin infant jaundice for babies of all races -- even those undergoing phototherapy treatment. A study of the device published in Pediatrics, the publication of the American Academy of Pediatrics, found that the Colormate® TLc-BiliTest(TM) System was effective in monitoring jaundice compared to current invasive techniques that involve taking blood from infants -- often repeatedly. Chromatics Color Sciences is in the business of color science..... Medical applications in addition to the detection and monitoring of bilirubin infant jaundice will require additional clinical trials and FDA clearance..... Certain of the matters discussed in this announcement contain forward- looking statements ....